DISEASE INDICATIONS: Leukemia
MANUFACTURER: Novartis Europharm Limited
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
Rydapt (midostaurin) is prescribed to treat newly diagnosed acute myeloid leukemia (AML), aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) in patients.